Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today releases its financial results for the quarter ending December 31, 2022 and provides a business update.
Recent Corporate Highlights:
- Announced initial patient data from UK NHS Miboko Study that demonstrates weight loss in 100% of participants – study to continue for 12 months.
- Received first U.S.-based purchase order for 5,000 proBEAT™ subscriptions from HealthFleet Inc., a leading telehealth provider focusing on care, coaching, and health recommendations. The purchase order consists of 75,000 proBEAT glucose sensors over an initial five month period and is valued at $500,000 in revenue.
- Entered into a Registered Direct Offering and concurrent Private Placement for gross proceeds of approximately $8.4 million (before expenses) in January 2023.
“We continue to build momentum with our UK programs, while initiating our foothold in the U.S. The recent purchase order from HealthFleet marks the beginning of our commercialization efforts in the U.S., integrating our proBEAT technology into HealthFleet’s RestoreHealth program to potentially improve diabetes management and weight loss. This is a significant step forward towards the integration of our sensor technology into existing diabetes management programs in the U.S.,” commented Nemaura CEO Dr. Faz Chowdhury. “With Miboko, the encouraging early patient data from our UK NHS Miboko study that demonstrated weight loss in 100% of participants is very encouraging and bodes well for the future of that program. There are obviously many weight loss programs on the market, but this early Miboko data exceeds the results seen in some of these other programs. With our balance sheet strengthened by the recent capital raise, we are better positioned to execute on our commercialization efforts and strategic goals in 2023.”
3Q23 Financial Summary:
- Reported revenue based on delivery of product from the purchase order from its UK licensee in 2021 with an anticipated gradual ramp of revenue expected in coming quarters.
- Net loss for the quarter was approximately $1.7million. Additional headcount was added to support the operational scale-up process, to continue building product inventory to fulfil existing purchase orders, and to support ongoing and future commercial sales activities.
- Cash and cash equivalents at December 31, 2022 were approximately $7.3 million.
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT diabetes program that is currently undergoing pilot studies.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking Statements:
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura Medical’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The U.S. Food and Drug Administration (the “FDA”) reserves the right to re-evaluate its decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
NEMAURA MEDICAL INC.
Condensed Consolidated Balance Sheets
| December 31, 2022 (Unaudited) | March 31, 2022 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | 7,340,840 | $ | 17,749,233 | ||||
| Prepaid expenses and other receivables | 1,217,237 | 750,167 | ||||||
| Accounts receivable - related party | 25,320 | 101,297 | ||||||
| Inventory | 2,352,407 | 1,487,771 | ||||||
| Total current assets | 10,935,804 | 20,088,468 | ||||||
| Property and equipment, net of accumulated depreciation | 581,903 | 532,508 | ||||||
| Intangible assets, net of accumulated amortization | 1,443,991 | 1,480,980 | ||||||
| Total other assets | 2,025,894 | 2,013,488 | ||||||
| Total assets | $ | 12,961,698 | $ | 22,101,956 | ||||
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 171,207 | $ | 136,310 | ||||
| Other liabilities and accrued expenses | 390,858 | 558,426 | ||||||
| Foreign currency contract | 1,075,692 | 440,196 | ||||||
| Notes payable, current portion | 11,512,711 | 19,188,724 | ||||||
| Deferred revenue | 69,681 | 259,256 | ||||||
| Total current liabilities | 13,220,149 | 20,582,912 | ||||||
| Notes payable, net of current portion | 8,557,548 | — | ||||||
| Deferred revenue, net of current portion | 1,042,710 | 1,052,960 | ||||||
| Total liabilities | 22,820,407 | 21,635,872 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ (deficit) equity: | ||||||||
| Common stock, $0.001 par value, 42,000,000 shares authorized and 24,103,196 and 24,102,866 shares issued and outstanding at December 31, 2022 and March 31, 2022 | 24,103 | 24,103 | ||||||
| Additional paid-in capital | 38,296,198 | 38,295,775 | ||||||
| Accumulated deficit | (47,192,364 | ) | (37,731,476 | ) | ||||
| Accumulated other comprehensive loss | (986,646 | ) | (122,318 | ) | ||||
| Total stockholders’ (deficit) equity | (9,858,709 | ) | 466,084 | |||||
| Total liabilities and stockholders’ (deficit) equity | $ | 12,961,698 | $ | 22,101,956 | ||||
NEMAURA MEDICAL INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(in Dollars, except Share Amounts)
| Three Months Ended December 31, | Nine Months Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Sales | $ | 3,017 | $ | 183,628 | $ | 77,044 | $ | 183,628 | ||||||||
| Cost of Sales | (2,971 | ) | (172,393 | ) | (75,327 | ) | (172,393 | ) | ||||||||
| Gross Profit | 46 | 11,235 | 1,717 | 11,235 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 393,747 | 412,341 | 980,862 | 987,711 | ||||||||||||
| General and administrative | 239,628 | 1,391,278 | 4,329,306 | 4,151,380 | ||||||||||||
| Total operating expenses | 633,375 | 1,803,619 | 5,310,168 | 5,139,091 | ||||||||||||
| Loss from operations | (633,329 | ) | (1,792,384 | ) | (5,308,451 | ) | (5,127,856 | ) | ||||||||
| Interest expense | (1,082,949 | ) | (1,639,184 | ) | (4,152,437 | ) | (5,141,701 | ) | ||||||||
| Net loss | (1,716,278 | ) | (3,431,568 | ) | (9,460,888 | ) | (10,269,557 | ) | ||||||||
| Other comprehensive loss: | ||||||||||||||||
| Foreign currency translation adjustment | 556,080 | (25,065 | ) | (864,328 | ) | (142,922 | ) | |||||||||
| Comprehensive loss | $ | (1,160,198 | ) | $ | (3,456,633 | ) | $ | (10,325,216 | ) | $ | (10,412,479 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.07 | ) | $ | (0.15 | ) | $ | (0.39 | ) | $ | (0.44 | ) | ||||
| Weighted average number of shares outstanding, basic and diluted | 24,103,196 | 23,313,629 | 24,102,976 | 23,244,345 | ||||||||||||
NEMAURA MEDICAL INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Nine Months Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
| Cash Flows From Operating Activities: | ||||||||
| Net loss | $ | (9,460,888 | ) | $ | (10,269,557 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 268,595 | 139,751 | ||||||
| Amortization of debt discount | 4,152,437 | 5,141,701 | ||||||
| Change in fair value of foreign currency contract | 635,494 | 199,522 | ||||||
| Changes in assets and liabilities: | ||||||||
| Prepaid expenses and other receivables | (467,070 | ) | 797,155 | |||||
| Inventory | (864,636 | ) | (533,656 | ) | ||||
| Accounts payable | 34,897 | (77,075 | ) | |||||
| Due to (from) related parties | 75,977 | (301,387 | ) | |||||
| Other liabilities and accrued expenses | (167,568 | ) | 264,786 | |||||
| Deferred revenue | (297,419 | ) | 285,266 | |||||
| Net cash used in operating activities | (6,090,181 | ) | (4,353,494 | ) | ||||
| Cash Flows From Investing Activities: | ||||||||
| Capitalized patent costs | (135,168 | ) | (60,241 | ) | ||||
| Capitalized software development costs | (27,879 | ) | (460,466 | ) | ||||
| Purchase of property and equipment | (275,758 | ) | (359,301 | ) | ||||
| Net cash used in investing activities | (438,805 | ) | (880,008 | ) | ||||
| Cash Flows From Financing Activities: | ||||||||
| Proceeds from issuance of common stock | 696 | 118,791 | ||||||
| Equity issuance cost paid | (273 | ) | (4,382 | ) | ||||
| Proceeds from issuance of notes payable | 4,700,000 | — | ||||||
| Proceeds from warrant exercise | — | 2,963,658 | ||||||
| Repayments of note payable | (7,974,282 | ) | (6,500,000 | ) | ||||
| Net cash used in financing activities | (3,273,859 | ) | (3,421,933 | ) | ||||
| Effect of exchange rate changes on cash | (605,548 | ) | (163,658 | ) | ||||
| Net decrease in cash | (10,408,393 | ) | (8,819,093 | ) | ||||
| Cash at beginning of period | 17,749,233 | 31,865,371 | ||||||
| Cash at end of period | 7,340,840 | 23,046,278 | ||||||
| Supplemental disclosure of non-cash financing activities: | ||||||||
| Release of prepayment from equity compensation | — | 50,000 | ||||||
| Monitoring fees related to notes payable | 1,522,372 | — | ||||||
